The gut microbiota in transplant patients

Research output: Contribution to journalReview article

Abstract

Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for developing infections due to underlying immunosuppression. Antibiotic use, and in HSCT recipients, the use of preparative regimens prior to transplantation can deplete gut commensal bacteria, resulting in intestinal dysbiosis. Emerging evidence in transplant patients, particularly HSCT, suggest that disturbances in gut microbiota populations are associated with a number of adverse outcomes. Here, we review the outcomes of HSCT and SOT recipients with gut microbiota imbalance or dysbiosis, explore the nascent field of gut microbiome therapeutic approaches including fecal microbiota transplantation and the use of precision probiotics in HSCT and SOT recipients.

Original languageEnglish (US)
Article number100614
JournalBlood Reviews
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Transplants
Hematopoietic Stem Cells
Dysbiosis
Gastrointestinal Microbiome
Probiotics
Immunosuppression
Transplantation
Anti-Bacterial Agents
Bacteria
Transplant Recipients
Infection
Population

Keywords

  • Colonization resistance
  • Fecal microbiota transplant
  • Gut microbiome
  • Microbiota
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The gut microbiota in transplant patients. / Chong, Pearlie Pao Ee; Koh, Andrew.

In: Blood Reviews, 01.01.2019.

Research output: Contribution to journalReview article

@article{c57a4b3f79df4f95bf8bdedfd8b231cf,
title = "The gut microbiota in transplant patients",
abstract = "Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for developing infections due to underlying immunosuppression. Antibiotic use, and in HSCT recipients, the use of preparative regimens prior to transplantation can deplete gut commensal bacteria, resulting in intestinal dysbiosis. Emerging evidence in transplant patients, particularly HSCT, suggest that disturbances in gut microbiota populations are associated with a number of adverse outcomes. Here, we review the outcomes of HSCT and SOT recipients with gut microbiota imbalance or dysbiosis, explore the nascent field of gut microbiome therapeutic approaches including fecal microbiota transplantation and the use of precision probiotics in HSCT and SOT recipients.",
keywords = "Colonization resistance, Fecal microbiota transplant, Gut microbiome, Microbiota, Transplant",
author = "Chong, {Pearlie Pao Ee} and Andrew Koh",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.blre.2019.100614",
language = "English (US)",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The gut microbiota in transplant patients

AU - Chong, Pearlie Pao Ee

AU - Koh, Andrew

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for developing infections due to underlying immunosuppression. Antibiotic use, and in HSCT recipients, the use of preparative regimens prior to transplantation can deplete gut commensal bacteria, resulting in intestinal dysbiosis. Emerging evidence in transplant patients, particularly HSCT, suggest that disturbances in gut microbiota populations are associated with a number of adverse outcomes. Here, we review the outcomes of HSCT and SOT recipients with gut microbiota imbalance or dysbiosis, explore the nascent field of gut microbiome therapeutic approaches including fecal microbiota transplantation and the use of precision probiotics in HSCT and SOT recipients.

AB - Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for developing infections due to underlying immunosuppression. Antibiotic use, and in HSCT recipients, the use of preparative regimens prior to transplantation can deplete gut commensal bacteria, resulting in intestinal dysbiosis. Emerging evidence in transplant patients, particularly HSCT, suggest that disturbances in gut microbiota populations are associated with a number of adverse outcomes. Here, we review the outcomes of HSCT and SOT recipients with gut microbiota imbalance or dysbiosis, explore the nascent field of gut microbiome therapeutic approaches including fecal microbiota transplantation and the use of precision probiotics in HSCT and SOT recipients.

KW - Colonization resistance

KW - Fecal microbiota transplant

KW - Gut microbiome

KW - Microbiota

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=85071668719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071668719&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2019.100614

DO - 10.1016/j.blre.2019.100614

M3 - Review article

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

M1 - 100614

ER -